Advantages, Dosage, Dangers, and Authorized Standing Defined – Swolverine

S23 is a nonsteroidal selective androgen receptor modulator (SARM) developed in the identical R&D period as different aryl-propionamide SARMs. It’s recognized for top AR efficiency with a status for marked suppression of pure testosterone—why many think about it an “advanced-only” analysis compound quite than a place to begin.

→ What this information covers: advantages folks search, actual dangers (suppression, cardiometabolic markers), community-reported dosing practices (for training, not recommendation), PCT concerns, legality/testing standing, and safer, lower-risk priorities for coaching and restoration.
→ Backside line up entrance: S23 can create a “laborious/lean” look and energy bump for some, however carries disproportionately excessive suppression and no FDA-approved medical use. It’s banned always in examined sport.

Preclinical work on S-series SARMs—together with S-23—reveals potent AR activation with reversible suppression of spermatogenesis and favorable lean-mass results in rodents. — Jones et al., Endocrinology (OUP Tutorial)

SARMs (together with S23) stay non-approved medicine within the U.S., with FDA warnings about critical security issues and enforcement towards bodybuilding merchandise. — U.S. FDA, Client Replace (U.S. Meals and Drug Administration)

All SARMs are prohibited in- and out-of-competition below WADA’s “Different Anabolic Brokers (S1.2)”—athletes topic to testing ought to keep away from fully. — WADA Prohibited Record 2025 (Wada Ama)

Why it’s controversial:
→ Efficiency vs. selectivity trade-offs: “tissue selective” in principle, however systemic androgen signaling nonetheless impacts HPG axis, lipids, and different biomarkers.
→ Human knowledge are missing; most mechanistic and efficacy/security insights come from animal research and neighborhood anecdotes—a poor foundation for danger prediction.
→ “Analysis chemical” provide chains imply variable purity and adulteration dangers.

Who this information is for:
→ Superior lifters evaluating danger realistically (and who prioritize labs/medical oversight).
→ Coaches/clinicians who want a transparent, harm-reduction-first explainer for consumer questions.
→ Examined athletes who want a reminder: it’s banned, full cease.

What Is S23?

S23 is a research-only SARM—a lab-made compound that sticks to the androgen receptor very tightly. It confirmed up in early pharma work (suppose: GTx, Inc.) as a possible male hormonal contraceptive as a result of it may construct lean tissue in animals and swap off sperm manufacturing whereas on-cycle, with restoration after stopping. That’s why lifters discuss it as “potent”—but additionally why suppression is such an enormous a part of the story. (OUP Tutorial)

→ In plain English: it’s not an permitted medication; it’s a robust AR “on-switch.” That energy cuts each methods—muscle-friendly signaling, but additionally significant sign to your HPG axis (your physique’s personal testosterone loop). The FDA has repeatedly warned that SARM-labeled merchandise are unapproved medicine and might carry actual security dangers, and in examined sports activities, all SARMs are banned year-round. (U.S. Meals and Drug Administration)

→ Chemistry snapshot (for ID solely): you’ll see S23 listed in databases by its lengthy IUPAC identify and CAS 1010396-29-8. These listings are helpful for confirming you’re studying about the identical molecule—not a inexperienced mild to make use of it. (PubChem)

Why folks even think about it:
→ Studies of a “tougher,” leaner look and noticeable energy at comparatively small quantities.
→ However that comes with a status for pronounced suppression, so it’s not a wise entry level for newcomers. (There’s no human dosing commonplace—all the pieces on-line is anecdote.) (OUP Tutorial)

Mechanism of Motion (How S23 Works)

At its core, S23 is a robust “on-switch” for the androgen receptor (AR). When it binds, the receptor flips from idle to lively, strikes into the nucleus, and activates (and off) units of genes that affect muscle protein synthesis, energy variations, and anti-catabolic signaling. That’s the straightforward model—right here’s the nuance that really issues:

→ Tissue-selective ≠ side-effect-free.
“SARMs are selective,” however not completely. Selectivity is determined by which co-regulator proteins are current in every tissue (muscle, bone, prostate, mind), how tightly S23 binds, and the way lengthy it sits there. The web impact: a number of muscle-friendly signaling, however nonetheless systemic androgen signaling your physique has to account for.

→ Why folks get the “tougher/leaner” look.
Sturdy AR activation nudges gene packages towards constructing/retaining contractile proteins and resisting breakdown while you’re weight-reduction plan or coaching laborious. Much less muscle loss throughout a minimize can learn visually as a “tougher” look. It’s not magic fat-loss; it’s principally higher retention of lean tissue below stress.

→ Why suppression is so widespread (and infrequently pronounced).
Your HPG axis (hypothalamus → pituitary → gonads) runs on suggestions. When AR signaling is excessive from S23, your mind reads “we’re good on androgens” and dials down GnRH → LH/FSH, which suppresses testicular testosterone and might cut back sperm manufacturing. That suggestions loop is why so many customers report needing sturdy restoration plans after stopping.

→ It’s potent—so small modifications matter.
S23 binds AR very tightly, so dose jumps can have outsized results. Extra receptor engagement doesn’t linearly equal “extra features”—it usually equals extra suppression and extra pressure on lipids, blood strain, temper/sleep, and different programs.

→ Selectivity can shift with context.
Caloric deficit vs. surplus, sleep debt, coaching quantity, and even different compounds you stack with S23 can change the steadiness of co-regulators and stress hormones. Translation: the identical dose can “really feel” completely different throughout phases—another excuse to keep away from chasing results by bumping dose.

→ What we don’t know (and why it issues).
There’s no validated human half-life or PK profile for S23. Most split-dosing recommendation on-line is guesswork. With out dependable PK, you may’t time bloodwork exactly or predict peaks/troughs—so conservative assumptions and frequent labs are the one accountable strategy.

Key takeaways (mechanism → follow):
→ S23 activates AR-driven muscle packages however turns down your personal T manufacturing through detrimental suggestions.
→ “Hardening” is especially lean-mass preservation below stress, not a fat-loss superpower.
→ Excessive efficiency means small will increase can escalate unwanted effects rapidly.
→ Unknown human PK = deal with all dosing folklore as unverified; if somebody makes use of it anyway, labs and guardrails are non-negotiable.

Advantages of S-23 (What the Analysis Really Exhibits)

Actuality test up entrance: there aren’t any managed human trials on S-23. What follows comes from preclinical (animal) research and medicinal-chemistry opinions—helpful for understanding biology, not ensures of leads to folks.

→ Lean-mass help in vivo
Throughout rat research, S-23 reveals clear myotrophic results (e.g., bigger levator ani muscle) and favorable body-comp alerts below androgen receptor (AR) activation. That’s the scientific root of its “hardening” status. (PubMed)

→ Physique-composition shifts (dose-responsive)
Preclinical work stories lean mass up and fats mass down as publicity will increase—in keeping with sturdy AR agonism driving protein synthesis and anti-catabolic pathways in vivo. (PMC)

→ Bone-anabolic alerts (preclinical)
Nonsteroidal SARMs—together with the S-series—repeatedly present constructive results on bone markers/density in animal fashions, aligning with AR-mediated skeletal advantages seen with different SARMs. (PMC)

→ Anabolic with comparatively decrease prostate stimulation vs. testosterone (in animals)
Head-to-head preclinical profiling suggests S-23 can improve muscle whereas producing much less prostate progress than classical androgens at studied doses—the “selective” in SARM. (PubMed)

→ Efficiency that helps protect tissue below stress
In fashions the place muscle is in danger (e.g., castration/orchiectomy paradigms), SARMs protect lean tissue and strength-related endpoints—an impact sample S-23 shares inside this class. (OUP Tutorial)

---

What this doesn’t imply

• S-23 is just not a validated fat-loss drug; any fats loss stays diet-driven. The constant preclinical sign is lean-mass preservation, not direct lipolysis. (Class-level proof, not human S-23 knowledge.) (PMC)

• Advantages include a trade-off: the identical efficiency that drives myotrophy is why S-23 was explored for male contraception—it suppresses LH/FSH and spermatogenesis throughout publicity in rats, with reversibility reported after discontinuation in that mannequin. (PubMed)

Backside line: The strongest proof for S-23’s “advantages” is preclinical—lean-mass help, body-comp and bone alerts, and tissue bias vs. testosterone in animals. With out human trials, magnitude, security, and sturdiness in folks stay unknown.

Dosage & Cycle Size (Academic Overview, Not Recommendation)

There’s no sugar-coating this: there aren’t any validated human dosing requirements for S-23—no peer-reviewed human pharmacokinetics, no medical half-life, no permitted indications. Every little thing you see on-line is anecdote. Deal with it that means.

→ What the analysis truly provides us

• Preclinical solely. S-23 was profiled in animals for male contraception: potent AR activation, lean-mass alerts, sturdy HPG-axis suppression—and reversibility after cessation in these fashions. That’s biology, not a dosing playbook. (PubMed)

• No human PK/half-life. Main reference listings determine S-23 however don’t present validated human dosing or half-life knowledge. Should you can’t time publicity, you may’t time labs or predict peaks/troughs with confidence. (DrugBank)

→ Why “break up dosing” recommendation on-line is shaky
With out human PK, assumptions about absorption, time-to-peak, or distribution are guesswork. Cut up dosing is usually copied from different SARMs or from stimulant playbooks—not from S-23 human knowledge. (There aren’t any.)

→ Cycle size: shortest sensible publicity
As a result of S-23 is high-potency and suppressive, danger usually scales with dose × time. A harm-reduction stance prioritizes minimal publicity and goal monitoring over chasing marginal beauty modifications. (Preclinical efficiency is precisely why warning issues.) (PubMed)

→ Monitoring framework (what accountable seems like)

• Earlier than: CBC, CMP (ALT/AST, creatinine/eGFR), fasting lipids, hormones (whole T, free T or calc, LH, FSH), BP/resting HR baseline.

• Throughout: Repeat CMP/lipids at ~3–4 weeks; observe BP, resting HR, sleep, temper, efficiency. If issues development the incorrect means, alter coaching first—don’t escalate publicity.

• After (restoration): Re-check hormones/lipids/CMP 3–6 weeks put up and proceed till baseline returns. No re-runs till each labs and signs normalize.
  These guardrails replicate the suppression and systemic alerts seen in animal work and the FDA’s broader security warnings round SARM-labeled merchandise. (PubMed)

→ Examined athletes: zero room for error
All SARMs (together with S-series) are banned always below WADA S1.2. Detection home windows could be unpredictable with research-chemical provide chains. Should you’re examined, avoidance is the one rational alternative. (Wada Ama)

Dangers & Facet Results (Analysis-Pushed, No Spin)

Context: There aren’t any managed human trials on S-23. Threat alerts come from (1) animal work on S-23 itself (potent AR activation with marked HPG-axis suppression), and (2) human stories and class-level knowledge on different SARMs (liver harm, lipid modifications, regulatory warnings). Learn this like a pre-flight guidelines.

Endocrine & Fertility

→ Sturdy suppression is the headline. In rat contraception fashions, S-23 constantly suppressed LH/FSH, lowered spermatogenesis, and did so in a dose-responsive method (reversible after discontinuation in these research). That’s the organic foundation for anticipating important testosterone suppression in folks, though human S-23 knowledge are missing. (PubMed)

Hepatic Alerts

→ Drug-induced liver harm (DILI) has been documented with SARMs (e.g., ligandrol/LGD-4033, ostarine/RX-24, RAD-140) in case collection and stories, together with biopsy-proven cholestatic patterns. Whereas these should not S-23 particularly, they point out a category danger that warrants labs and warning. (PMC)

Lipids & Cardiometabolic

→ HDL tends to fall with SARM publicity. Human and translational research on SARMs present important HDL-C reductions (with variable results on LDL/TG) and mechanistic shifts in HDL subspecies—alerts that push you to observe lipids, blood strain, and coaching stress. (PMC)

Regulatory & Security Warnings

→ The FDA has repeatedly warned that SARM-labeled bodybuilding merchandise are unapproved medicine linked to critical security issues (liver, cardiac, stroke danger) and has taken enforcement motion towards entrepreneurs. Translation: no approval, no validated dosing, and actual security flags. (U.S. Meals and Drug Administration)
→ For athletes, all SARMs are prohibited year-round below WADA S1.2; detection home windows are unpredictable throughout gray-market merchandise. (Wada Ama)

CNS, Dermatologic, and Different Androgenic Alerts

→ Group and clinician stories across the SARM class embrace sleep fragmentation, irritability, low temper (particularly post-cycle), pimples/oily pores and skin, hair shedding in predisposed customers, and shifts in resting HR/BP—in keeping with potent AR modulation plus endocrine disruption. (Mechanistic alignment from S-series preclinical work + class surveillance.) (PMC)

---

What to Monitor (sensible guardrails)

→ Earlier than: CBC; CMP (ALT/AST, creatinine/eGFR); lipid panel; hormones (whole T, free T or calculated, LH, FSH); BP & resting HR baseline. (Suppression + hepatic + lipid rationale.) (PubMed)
→ Throughout (≈ week 3–4): CMP, lipids; observe BP, resting HR, sleep, temper, efficiency. If markers development the incorrect means, repair coaching, sleep, and food plan first—don’t escalate dose. (PMC)
→ After (restoration): Repeat hormones/lipids/CMP 3–6 weeks put up to verify axis rebound and hepatic/lipid normalization earlier than resuming high-stress coaching phases. (PubMed)

Pink Flags → Cease & Search Care

Chest ache/shortness of breath; persistent BP ≥140/90; jaundice, darkish urine, RUQ ache; extreme fatigue; main temper modifications or anhedonia; ALT/AST spikes or sharp HDL collapse on labs. (These mirror the FDA’s security issues and revealed DILI instances.) (U.S. Meals and Drug Administration)

Backside line: S-23’s efficiency is precisely why suppression is anticipated; class knowledge add liver and lipid danger on prime. With no human S-23 dosing/PK, the one accountable stance is conservative publicity, goal labs, and a transparent exit plan—and for examined athletes, zero use. (Wada Ama)

Submit-Cycle Remedy (PCT) Issues

S23’s calling card is powerful suppression. If somebody runs it anyway, assume you’ll want an actual restoration plan—measured by labs, not vibes.

→ Why PCT is normally essential
S23 drives AR signaling excessive sufficient that your hypothalamus/pituitary learn “androgens are plentiful,” dialing down GnRH → LH/FSH. The consequence: endogenous testosterone drops and sperm parameters can tank. Coming off, you’re relying in your axis to restart—PCT is about nudging that course of when you shield well being and coaching.

→ What “good PCT” means (ideas, not prescriptions)

• Goal baselines: Earlier than the final on-cycle week, get whole T, free T (or calc), LH, FSH, plus lipids and CMP (ALT/AST, creatinine/eGFR).

• Timing the beginning: Start restoration help after the compound’s results have meaningfully waned (with S23, human PK is unknown—err on a brief washout quite than stacking uncertainty).

• Period: Plan for 4–6 weeks of restoration help as a beginning body, then lengthen or taper primarily based on labs/signs—not the calendar.

• Coaching throughout PCT: Scale back systemic fatigue—dial in quantity, depth, and frequency to prioritize high quality reps and method. Insert a deload in week 1–2 of PCT.

• Diet throughout PCT: Slight calorie bump to upkeep or +5–10%, 0.8–1.0 g protein/lb, constant carbs round coaching, micronutrient sufficiency (iodine, selenium, zinc from meals first).

• Life-style: 7–9 hours sleep, alcohol at or close to zero, handle stress (HRV/resting HR are helpful actuality checks).

→ What to observe (and when to alter course)

• Weeks 2–3 of PCT: Repeat LH, FSH, whole/free T, lipids, CMP. Search for up-trending LH/FSH and rising T with signs enhancing (power, sleep, drive).

• If labs stall or worsen: Prolong restoration, tighten coaching stress, reassess sleep/steps, and think about clinician-guided choices.

• Pink flags: Persistently low temper, marked fatigue, BP elevation, pronounced ALT/AST rise, or any regarding signs → escalate to a clinician promptly.

→ Guardrails that really assist

• Don’t stack extra compounds “to really feel regular.” Restoration is a hormonal and behavioral course of.

• Maintain conditioning in, however make it repeatable (zone 2 or tempo work) to help lipids, BP, and temper with out pounding restoration.

• Dietary supplements to prioritize: fundamental, low-risk pillars—creatine monohydrate, omega-3s, electrolytes, vitamin D if poor. Skip the “PCT miracle” blends.

→ When to contemplate medical assist

• No upward motion in LH/FSH or testosterone by week 4–6 post-cycle

• Extreme temper/sleep disruption or sexual operate not enhancing

• Lipids or liver enzymes that stay materially off-baseline

Dosage & Cycle Size (Academic Overview, Not Recommendation)

There’s no medical playbook for S-23—no validated human half-life, dosing, or PK. Something you see on-line is anecdote, not proof. Learn this as a framework for security pondering, not a how-to.

→ What we truly know

• Preclinical solely. S-23 is potent and suppressive in animal fashions. Helpful for understanding danger, not for calculating doses.

• Human PK unknown. And not using a verified half-life, “break up dosing” schedules you see on boards are guesswork. Peaks, troughs, and washout timing are unpredictable.

• Threat scales with publicity. Extra milligrams × extra weeks = extra suppression and extra probabilities to ding lipids, liver markers, temper, and sleep.

→ Sensible guardrails (if somebody makes use of it anyway)

• Lowest efficient publicity, shortest sensible period. Assume minimalist trial, not “blast.”

• No stacking “simply because.” Overlapping toxicity (lipids, liver, BP, CNS) compounds rapidly.

• Coaching first. Repair quantity, depth, sleep, and diet earlier than touching dose—S-23 magnifies no matter system you already run.

• Deloads are non-negotiable. Schedule one in the course of the again half of the run or on the entrance of restoration to maintain fatigue in test.

→ Monitoring cadence (goal > vibes)

• Earlier than: CBC; CMP (ALT/AST, creatinine/eGFR); lipid panel; hormones (whole T, free T or calculated, LH/FSH); baseline BP and resting HR.

• Throughout (week 3–4, then as wanted): CMP, lipids; observe BP, resting HR, sleep, temper, efficiency notes. If traits slide, alter coaching/sleep first—not dose.

• After (restoration): Repeat hormones/lipids/CMP 3–6 weeks put up; don’t think about one other run till labs and signs normalize.

→ Cycle-length mindset

• Conservative home windows solely. Shorter runs restrict cumulative suppression and make restoration extra predictable.

• Plan the exit on day one. Guide your post-cycle labs and set your coaching/diet for restoration earlier than you begin.

→ Pink-flag checkpoints (cease and reassess)

• Persistent BP ≥140/90, notable resting-HR rise

• Marked ALT/AST elevation, darkish urine, jaundice, RUQ ache

• Main temper modifications, sleep breakdown, or anhedonia

• Sharp HDL drop or LDL spike on interim labs

→ Examined athletes

• SARMs are banned year-round. With gray-market variability and unknown metabolites, detection home windows are unpredictable. Should you’re examined, the one protected transfer is don’t use.

Stacking & Combos (Proceed with Warning)

Brief model: S-23 is already high-potency and suppressive. Stacking it with different SARMs or orals normally means extra suppression, extra liver/lipid pressure, and extra variables you may’t management. The FDA explicitly warns that SARM-labeled merchandise are unapproved medicine linked to critical dangers; in examined sport, they’re banned year-round. (U.S. Meals and Drug Administration)

Frequent stacks folks discuss — and why danger compounds

→ S-23 + RAD-140 or LGD-4033. Customers chase “hardness + dimension,” however each RAD-140 and LGD-4033 have documented cholestatic drug-induced liver harm (DILI) instances. Additive liver danger + deeper endocrine suppression = dangerous commerce. (PMC)
→ S-23 + one other SARM (“kitchen-sink” SARM stacks). Class knowledge present HDL drops with SARMs; stacking makes lipid headwinds worse whereas providing diminishing returns. (PMC)
→ S-23 + oral AAS (e.g., winstrol, anavar). Even when S-23 isn’t 17-aa, the overlapping hepatic and lipid toxicity profile compounds—and sourcing/label accuracy within the grey market is its personal danger multiplier. (U.S. Meals and Drug Administration)
→ S-23 + “PCT in a bottle” in the course of the run. Case collection word DILI from SARMs and/or PCT adjuncts; extra tablets ≠ extra security. (PMC)

What to not mix (overlapping-toxicity watchlist)

→ Any hepatotoxic oral (AAS, prohormones, “designer” steroids): stacks elevate DILI odds; case literature retains rising. (PMC)
→ A number of SARMs without delay: anticipate bigger HDL suppression and tougher recoveries; there isn’t any medical upside demonstrated to justify the danger. (PMC)
→ Stimulant-heavy fats burners: add BP/HR pressure to a compound class already linked with lipid deterioration; not a wise pairing. (PMC)
→ Something in case you’re a examined athlete: SARMs are prohibited below WADA S1.2 all 12 months; detection home windows are unpredictable. (Wada Ama)

Smarter helps to prioritize as a substitute of stacking (lower-risk pillars)

→ Sleep & restoration: 7–9 hours/evening, scheduled deloads, steps/zone-2—these enhance lipids, BP, and temper with out including hepatic load. (Pairs instantly towards the lipid/BP headwinds noticed with SARMs.) (PMC)
→ Electrolytes & hydration: efficiency and BP stability with zero endocrine draw back.
→ Protein & creatine monohydrate: helps energy/lean mass with out liver/lipid penalties seen in SARM stacks; creatine is among the many most studied, protected ergogenics.
→ Omega-3s (EPA/DHA): cardio-metabolic help when you monitor lipids—helpful in a category that tends to knock HDL down. (PMC)
→ Vitamin D if poor: repair the deficiency; don’t “stack” extra SARMs.

Backside line: S-23 already carries suppression, lipid, and potential hepatic alerts. Stacking with SARMs or orals principally multiplies danger with out evidence-based upside. If somebody insists on working it, maintain it solo, shortest sensible period, with labs, and construct your outcomes on sleep, diet, and programming—not on a much bigger complement pile. (U.S. Meals and Drug Administration)

S-23 vs. Different Compounds (What the Proof Suggests)

Fast body: S-23 sits within the “very potent, very suppressive” bucket with no human PK or dosing knowledge. Examine it to what we do know from different SARMs and from oral AAS.

S-23 vs RAD-140 (Testolone)

Efficiency/suppression: S-23 binds AR extraordinarily tightly (Kᵢ ≈ 1.7 nM in assay work), which helps clarify its status for hardness and pronounced HPG-axis suppression in animals. RAD-140 can also be high-affinity, however the knowledge that matter for danger are the human case stories: biopsy-proven cholestatic DILI has been documented after RAD-140 use. Backside line: in case your purpose is to reduce draw back, S-23’s suppression + RAD’s documented DILI are each heavy prices. (caymanchem.com)

Facet-effect profile: RAD-140 has a number of revealed liver-injury stories (together with steroid-responsive cholestatic harm); S-23 lacks human case collection however carries class-level hepatic and lipid danger warnings from FDA for SARMs usually. Each are prohibited always in examined sport. (PMC)

---

S-23 vs LGD-4033 (Ligandrol/VK5211)

Measurement vs hardness: LGD-4033 has the most human knowledge on this group. In wholesome males (Part 1), 1 mg/day for 21 days elevated lean mass with a 24–36 h half-life (once-daily PK). That profile skews towards “dimension” at low medical doses, whereas S-23’s lore is “hardness” through laborious AR signaling—however that’s preclinical + anecdote, not head-to-head knowledge. (PubMed)

Restoration: LGD has human PK to time washouts and labs; S-23 doesn’t. Nonetheless, LGD additionally carries documented DILI instances in real-world use, and SARMs as a category are inclined to decrease HDL—so restoration isn’t trivial. S-23’s sturdy suppression in animals suggests a harder hormonal rebound even when hepatic occasions are much less documented. (Lippincott Journals)

Takeaway: LGD-4033 = some human medical knowledge + recognized DILI case stories; S-23 = no human PK + excessive suppression. Each are banned in sport. (PubMed)

---

S-23 vs YK-11 / “myostatin” brokers

Claims vs plausibility: The “myostatin inhibitor” pitch for YK-11 traces to cell knowledge exhibiting follistatin upregulation in C2C12 myoblasts (in vitro). That’s not human proof—and newer preclinical work flags potential neurotoxicity/oxidative stress issues. Doping-control research exist for metabolism detection, however there aren’t any managed human efficacy/security trials. Towards that backdrop, S-23 at the least has in vivo rat knowledge and constant suppression alerts; YK-11’s “myostatin block” stays unproven in people. (PubMed)

Takeaway: Deal with YK-11’s myostatin claims as hypothesis-level (cell fashions), not medical actuality. If the purpose is “hardening,” coaching/food plan manipulation beats betting on a compound with no human knowledge and rising security questions. (PubMed)

---

S-23 vs Oxandrolone (Anavar) — oral AAS reference level

Efficacy sign: In contrast to S-23, oxandrolone has actual human medical knowledge (e.g., burn restoration) exhibiting will increase in lean physique mass, energy, and purposeful restoration below medical supervision. (PMC)

Threat & regulation: Oxandrolone is a 17-α-alkylated AAS with well-documented HDL↓/LDL↑ results and hepatotoxicity danger on its FDA label—therefore intense monitoring and controlled-substance standing. In the meantime, S-23 isn’t permitted in any respect; SARMs in “bodybuilding merchandise” carry FDA warnings for critical questions of safety, and all are prohibited in sport. (FDA Entry Knowledge)

Use-case actuality: If somebody is evaluating “analysis SARM” to a prescription AAS, acknowledge the commerce: S-23 has no human dosing/PK and unsure purity within the grey market; oxandrolone has formal labeling and trials however brings recognized lipid/liver liabilities and authorized controls. Neither is a free lunch. (FDA Entry Knowledge)

---

Backside line (zoomed out)

• S-23 vs RAD-140: S-23 → extra suppression; RAD-140 → extra human DILI stories. Each banned. (PMC)

• S-23 vs LGD-4033: LGD has human PK + lean-mass knowledge and DILI instances; S-23 lacks human PK however reveals sturdy suppression preclinically. (PubMed)

• S-23 vs YK-11: YK-11’s “myostatin” angle is cell-culture degree with no human trials and rising security issues; deal with as unproven. (PubMed)

• S-23 vs Oxandrolone: Oxandrolone has medical efficacy in area of interest settings however clear HDL/liver dangers and authorized controls; S-23 has no human dosing knowledge and sits below FDA warnings for SARM-labeled merchandise. (PMC)

Authorized Standing of S23

Right here’s a breakdown of the place S23 stands legally — vital to know for the reason that compound resides in a legally murky zone.

United States

• S23 and different selective androgen receptor modulators (SARMs) should not permitted by the U.S. Meals & Drug Administration (“FDA”) for any medical use. They’re thought-about unapproved medicine. (U.S. Meals and Drug Administration)

• Firms can’t legally market S23 (or any SARM) as a dietary complement or as an over-the-counter drug within the U.S. (Council for Accountable Diet)

• The U.S. Senate launched payments aiming to categorise SARMs below the Managed Substances Act (for instance, the “SARMs Management Act of 2018”). The standing of S23 particularly below these legal guidelines could differ by jurisdiction. (Congress.gov)

• From a sports activities doping perspective, the World Anti‑Doping Company (“WADA”) prohibits all SARMs, together with S23, for athletes out and in of competitors. They fall below “Different Anabolic Brokers (S1.2)”. (NPC Whats up)

Worldwide / Different Issues

• As a result of S23 is taken into account a analysis chemical or investigational compound, its authorized regulation varies considerably by nation. In lots of jurisdictions, advertising and marketing it as a complement or human-use product is illegitimate. (Wikipedia)

• Even when offered on-line, merchandise labelled “analysis use solely” or “not for human consumption” should violate native drug, complement, or health-regulation legal guidelines. These labels do not assure legality. (PMC)

Key Sensible Takeaways

• Should you discover S23 marketed as a “complement” or “efficiency enhancer” within the U.S., that advertising and marketing is probably going unlawful below FDA coverage.

• Athletes ruled by anti-doping guidelines should deal with S23 as prohibited always; even a hint may result in sanctions.

• Authorized danger consists of not solely regulatory/itemizing points, but additionally product purity and legal responsibility danger — unapproved compounds usually lack commonplace manufacturing controls.

• For non-athletes, whereas private possession/use could not all the time set off legal prosecution (relying on jurisdiction), purchases and labeling can nonetheless run afoul of import/export, prescription-drug, or supplement-fraud legal guidelines.

---

Conclusion

S-23 sits on the far finish of the SARM spectrum: potent AR signaling, excessive suppression, zero human dosing/PK, and no medical approval. Preclinical knowledge clarify the “hardening” status (lean-mass preservation in animals), however additionally they clarify the associated fee—sturdy HPG-axis shutdown, class-level lipid and hepatic issues, and a everlasting spot on the WADA banned checklist. In plain phrases: the “upside” is theoretical; the downsides are actual.

What sensible lifters do as a substitute

• Construct your look on coaching readability (progressive overload, trustworthy RPE, deliberate deloads).

• Lock in diet (enough protein, constant carbs round coaching, fiber and micros).

• Prioritize sleep and stress (7–9 hours, steps/zone-2, caffeine self-discipline).

• Use well-supported fundamentals (creatine monohydrate, omega-3s, electrolytes, vitamin D if poor) and maintain labs for actual well being monitoring—to not justify dangerous cycles.

Backside line: Should you’re a examined athlete, the reply is easy—don’t contact SARMs. Should you’re not, the proof nonetheless factors to a greater play: skip unapproved, extremely suppressive analysis chemical compounds and spend money on the basics that really scale—coaching high quality, restoration, diet, and consistency.

---

Academic disclaimer: This information is for info solely and isn’t medical recommendation. S-23 and different SARMs should not FDA-approved for any use, could carry critical well being dangers, and are prohibited in sport always. All the time seek the advice of a certified healthcare skilled earlier than making selections that have an effect on your well being.